Acute demyelinating polyneuropathy induced by nivolumab
- 26 August 2017
- journal article
- letter
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 89 (4), 435-437
- https://doi.org/10.1136/jnnp-2017-316510
Abstract
A 66-year-old man was diagnosed with NSCLC and developed adrenal metastases. Although the patient was treated with two courses of carboplatin [AUC (area under the curve) 6] and nab-paclitaxel (100 mg/m2), bilateral swelling of cervical lymph nodes and adrenal metastatic lesions expanded, and he received nivolumab treatment. Five days after two courses of nivolumab treatment, he developed muscle weakness of the lower limbs (day 1). His limb weakness rapidly progressed, and he became bed-bound. The thoracic CT imaging showed reduction of the lesions of NSCLC. However, because irAE secondary to nivolumab treatment was suspected, the patient received prednisolone (60 mg/day) on day 9, and nivolumab treatment was discontinued. Despite the administration of prednisolone, his symptoms worsened and he was then transferred to our hospital on day 16. Neurological examination showed paraesthesia of the distal limbs, severe limb weakness and absence of deep tendon reflexes of the four extremities, but no disturbance of the cranial nerves. The results of the laboratory examinations were as follows: potassium (3.9 mmol/L, normal 3.6–4.8), …Keywords
Funding Information
- Japan Agency for Medical Research and Development
- Health and Labour Sciences Research Grant on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan
- Ministry of Education, Culture, Sports, Science and Technology of Japan
This publication has 5 references indexed in Scilit:
- Pembrolizumab-Induced Demyelinating PolyradiculoneuropathyThe New England Journal of Medicine, 2016
- Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case reportJapanese Journal of Clinical Oncology, 2016
- Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanomaJapanese Journal of Clinical Oncology, 2015
- Guillain–Barré syndrome with IgM antibody to the ganglioside GalNAc–GD1aJournal of Neuroimmunology, 2001
- N‐acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain‐Barré syndromeAnnals of Neurology, 1994